Skip to main content
Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples
  • Brian D. Piening, Molecular Genomics Laboratory, Providence Portland Medical Center, Portland, OR; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Cancer Center, Portland, OR.
Document Type
Publication Date
  • oregon,
  • portland,
  • chiles,
  • genomics

Comprehensive genomic profiling (CGP) is becoming standard of care for cancer and allows pathology labs to consolidate individual biomarkers into a single NGS assay. It enables the assessment of all key biomarkers cited in guidelines and clinical trials using a minimal amount of formalin-fixed, paraffin-embedded (FFPE) tissue while increasing the chance of finding a positive biomarker for every sample.

Illumina’s TruSight Oncology 500 High-Throughput (TSO500 HT)assay enables labs to perform in-house CGP with scalability on a NovaSeq 6000 platform.

In this CellPress webinar, Brian Piening of Providence Cancer Center will discuss why his team decided to implement in-house CGP and will share analytical performance data from their TSO500_HT runs. He will also provide details of the center’s end-to-end workflow, including the data analysis flow and how they build their final reports.

Clinical Institute
Earle A. Chiles Research Institute
Citation Information
Brian D. Piening. "Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples" Illumina (2020)
Available at: